Stocksigma LogoStocksigma Logo

Amanta Healthcare Reports Strong Q2 FY27 Growth and Commissioning of SteriPort Line 3

Amanta Healthcare posted Q2 FY27 revenue of ₹83.13 Cr, up 17.3% YoY, with EBITDA at ₹17.95 Cr (21.6% margin) and PAT rising 303% YoY to ₹4.86 Cr

Amanta Healthcare Reports Strong Q2 FY27 Growth and Commissioning of SteriPort Line 3

Amanta Healthcare Ltd · Investor Presentation · 04 Nov 2026, 5:33 pm

Amanta Healthcare Reports Strong Q2 FY27 Growth and Commissioning of SteriPort Line 3 Amanta Healthcare posted Q2 FY27 revenue of ₹83.13 Cr, up 17.3% YoY, with EBITDA at ₹17.95 Cr (21.6% margin) and PAT rising 303% YoY to ₹4.86 Cr. H1 FY27 revenue reached ₹151.94 Cr with PAT of ₹8.17 Cr. SteriPort Line 3 was commissioned in early Sep'26, expanding capacity by 75% to 11.6 Cr bottles and targeting ~₹60 Cr FY27 revenue. Upcoming SVP expansion in Q1 FY28 will boost capacity to 31.7 Cr units, supporting management's medium-term target of 20%+ revenue CAGR and 25%+ EBITDA margin.

Original exchange filing (PDF)

More announcements from Amanta Healthcare Ltd

All Amanta Healthcare Ltd announcements